Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.34B | 2.02B | 2.81B | 1.68B | 836.42M | Gross Profit |
274.25M | 450.41M | 627.69M | 375.00M | 202.73M | EBIT |
-16.86M | 112.71M | 273.11M | 139.30M | 15.97M | EBITDA |
3.99M | 129.34M | 285.14M | 152.35M | 2.41M | Net Income Common Stockholders |
-14.56M | 72.63M | 188.46M | 132.00M | -12.14M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
81.63M | 17.09M | 3.60M | 1.04M | 1.60M | Total Assets |
589.25M | 679.32M | 947.84M | 732.81M | 356.97M | Total Debt |
3.87M | 5.27M | 157.75M | 195.49M | 73.15M | Net Debt |
-77.76M | -11.83M | 154.14M | 194.45M | 71.55M | Total Liabilities |
170.29M | 205.92M | 490.62M | 435.28M | 202.06M | Stockholders Equity |
418.96M | 473.39M | 457.22M | 297.53M | 154.38M |
Cash Flow | Free Cash Flow | |||
111.40M | 234.52M | 125.26M | -92.79M | 22.59M | Operating Cash Flow |
120.12M | 248.50M | 134.05M | -85.62M | 27.20M | Investing Cash Flow |
-8.71M | -13.78M | -43.87M | -34.05M | -4.62M | Financing Cash Flow |
-46.85M | -221.24M | -87.60M | 119.09M | -22.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $1.08B | 26.44 | 8.37% | ― | 3.71% | 1.32% | |
69 Neutral | $1.04B | 39.43 | 11.28% | ― | 30.04% | 43.47% | |
54 Neutral | $868.68M | 18.62 | -21.08% | ― | -18.13% | -215.78% | |
52 Neutral | $5.15B | 3.05 | -44.13% | 2.84% | 16.42% | -0.48% | |
51 Neutral | $1.17B | 344.25 | 42.49% | ― | 9.05% | ― | |
47 Neutral | $458.64M | ― | -4.00% | ― | -29.16% | -140.16% | |
33 Underperform | $14.07M | ― | -951.52% | ― | -0.70% | -2.38% |
Cross Country Healthcare announced its financial results for the first quarter of 2025, showing a consolidated revenue of $293.4 million, which represents a 23% decrease year-over-year. Despite the decline in revenue, the company reported growth in its Homecare and Physician Staffing segments, with double-digit revenue increases. The company maintained a strong balance sheet with $81 million in cash and no debt as of March 31, 2025. The company is also in the process of a merger with Aya Healthcare, expected to be completed in the second half of the year.
Spark’s Take on CCRN Stock
According to Spark, TipRanks’ AI Analyst, CCRN is a Neutral.
Cross Country Healthcare’s overall score is moderate due to strong cash flow and a stable balance sheet, offset by challenges in profitability and negative market momentum. The stock’s valuation is unattractive due to recent losses, though operational strengths and a strong balance sheet provide some support.
To see Spark’s full report on CCRN stock, click here.
On March 5, 2025, Cross Country Healthcare announced its financial results for the fourth quarter and full year of 2024, revealing a decrease in revenue and profit margins compared to the previous year. Despite a net loss attributable to common stockholders and a decline in adjusted EBITDA, the company experienced growth in its Physician and Homecare Staffing segments and maintained a strong balance sheet with $82 million in cash and no debt. The company also repurchased over 2.4 million shares of common stock in 2024 and secured a three-year contract renewal with its largest managed service program. As the company awaits the closing of a pending transaction with Aya Healthcare, it continues to focus on delivering clinical excellence to meet client needs in a competitive market.